<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>How Positive Phase 3 Results for Orforglipron at Chugai Pharmaceutical (TSE:4519) Changed Its Investment Story — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">How Positive Phase 3 Results for Orforglipron at Chugai Pharmaceutical (TSE:4519) Changed Its Investment Story</h2>
    <div class="badge">2025-09-08T14:15:51+00:00</div>
    <ul>
      <li>Uncover how Chugai Pharmaceutical&#x27;s forecasts yield a ¥8082 fair value, a 21% upside to its current price.</li>
<li>This projection is based on a 4.9% annual revenue growth rate and represents a ¥121.5 billion increase in earnings from the current ¥395.4 billion.</li>
<li>Read the full narrative on Chugai Pharmaceutical (it&#x27;s free!) Chugai Pharmaceutical&#x27;s outlook forecasts ¥1,381.4 billion in revenue and ¥516.9 billion in earnings by 2028.</li>
<li>How Positive Phase 3 Results for Orforglipron at Chugai Pharmaceutical (TSE:4519) Changed Its Investment Story - On August 26, 2025, Chugai Pharmaceutical reported that Eli Lilly announced positive topline Phase 3 result</li>
<li>Exploring Other Perspectives Two unique fair value estimates from the Simply Wall St Community range from ¥8,082 to ¥8,689 per share.</li>
<li>These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer&#x27;s.</li>
<li>The end of cancer?</li>
    </ul>
    <p>
      <a class="btn" href="https://x.com/intent/tweet?text=How%20Positive%20Phase%203%20Results%20for%20Orforglipron%20at%20Chugai%20Pharmaceutical%20%28TSE%3A4519%29%20Changed%20Its%20Investment%20Story%0A%E2%80%A2%20Uncover%20how%20Chugai%20Pharmaceutical%27s%20forecasts%20yield%20a%20%C2%A58082%20fair%20value%2C%20a%2021%25%20upside%20to%20its%20current%20price.%0A%E2%80%A2%20This%20projection%20is%20based%20on%20a%204.9%25%20annual%20revenue%20growth%20rate%20and%20represents%20a%20%C2%A5121.5%20billion%20increase%20in%20earnings%20from%20the%20current%20%C2%A5395.4%20billion.%0A%E2%80%A2%20Read%20the%20full%20narrative%20on%20Chugai%20Pharmaceutical%20%28it%27s%20free%21%29%20Chugai%20Pharmaceutical%27s%20outlook%20forecasts%20%C2%A51%2C381.4%20billion%20in%20revenue%20and%20%C2%A5516.9%20billion%20in%20earnings%20by%202028.%0A%E2%80%A2%20How%20Positive%20Phase%203%20Results%20for%20Orforglipron%20at%20Chugai%20Pharmaceutical%20%28TSE%3A4519%29%20Changed%20Its%20Investment%20Story%20-%20On%20August%2026%2C%202025%2C%20Chugai%20Pharmaceutical%20reported%20that%20Eli%20Lilly%20announced%20positive%20topline%20Phase%203%20result%0A%E2%80%A2%20Exploring%20Other%20Perspectives%20Two%20unique%20fair%20value%20estimates%20from%20the%20Simply%20Wall%20St%20Community%20range%20from%20%C2%A58%2C082%20to%20%C2%A58%2C689%20per%20share.%0A%E2%80%A2%20These%2029%20emerging%20AI%20stocks%20are%20developing%20tech%20that%20will%20allow%20early%20identification%20of%20life%20changing%20diseases%20like%20cancer%20and%20Alzheimer%27s.%0A%E2%80%A2%20The%20end%20of%20cancer%3F&url=https%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Fhow-positive-phase-3-results-for-orforglipron-at-chugai-pharmaceutical-tse-4519%2F" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a class="btn" href="https://finance.yahoo.com/news/positive-phase-3-results-orforglipron-141551068.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>